ArticlePloS one2023

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.

Alessio Aghemo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.